Hikma Ventures Invests in Octave Bioscience, a Precision Care Platform Focused on Multiple Sclerosis and Other Neurodegenerative Diseases
Thursday, July 27, 2023
Hikma Pharmaceuticals PLC (Hikma), a multinational pharmaceutical company, has made a strategic investment through its venture capital arm, Hikma Ventures, in Octave Bioscience. Octave is a pioneering developer of a precision care platform designed to accurately and objectively measure and manage complex and costly neurodegenerative diseases, with its initial focus on multiple sclerosis (MS).
Octave's co-founders, William Hagstrom (CEO) and Melinda Thomas (COO), have created a state-of-the-art precision care solution that provides comprehensive, scientific insights into a patient's disease progression over time. This innovation aims to address the significant unmet needs in the MS space, which currently faces challenges such as outdated diagnostic tools, limited technological advancements, and inadequate support for neurodegenerative diseases.
Lana Ghanem, Managing Director of Hikma Ventures, expressed enthusiasm about Octave's precision care solution and its potential to transform the treatment and management of MS. The platform offers a holistic view of a patient's disease activity, enabling physicians and patients to make better-informed decisions about their care.
Hikma Ventures' investment aligns with Hikma's role as a leading provider of MS treatments in the Middle East and North Africa. Through this partnership, Hikma aims to improve patient outcomes and advance digital health solutions in the field of neurodegenerative diseases.
William Hagstrom also shared his appreciation for Hikma Ventures' collaborative approach in identifying and partnering with companies like Octave that have the potential to revolutionize neurodegenerative disease management with digital health solutions. The partnership will enable Octave Bioscience to expand its precision medicine solution to reach more MS patients and explore opportunities in other neurodegenerative diseases, such as Parkinson's and Alzheimer's.
The investment comes at a crucial time, as MS is considered an important disease area with underserved patients and high unmet needs across diagnostics and care management. Octave Bioscience plans to utilize the funding to support commercialization efforts in the MS space and further explore expansion opportunities in other neurodegenerative diseases, addressing critical challenges faced by these patient populations.
